97 related articles for article (PubMed ID: 32070858)
1. Infections in patients diagnosed with multiple sclerosis: A multi-database study.
Persson R; Lee S; Ulcickas Yood M; Wagner Usn Mc CM; Minton N; Niemcryk S; Lindholm A; Evans AM; Jick SS
Mult Scler Relat Disord; 2020 Jun; 41():101982. PubMed ID: 32070858
[TBL] [Abstract][Full Text] [Related]
2. Risk of acute respiratory infection and acute cardiovascular events following acute respiratory infection among adults with increased cardiovascular risk in England between 2008 and 2018: a retrospective, population-based cohort study.
Davidson JA; Banerjee A; Smeeth L; McDonald HI; Grint D; Herrett E; Forbes H; Pebody R; Warren-Gash C
Lancet Digit Health; 2021 Dec; 3(12):e773-e783. PubMed ID: 34823706
[TBL] [Abstract][Full Text] [Related]
3. Physical and mental health comorbidity is common in people with multiple sclerosis: nationally representative cross-sectional population database analysis.
Simpson RJ; McLean G; Guthrie B; Mair F; Mercer SW
BMC Neurol; 2014 Jun; 14():128. PubMed ID: 24925477
[TBL] [Abstract][Full Text] [Related]
4. Interplay between age and disease-modifying treatments in influencing infection risk in multiple sclerosis.
Jacober SLS; Disanto G; Sacco R; Meng D; Mallucci G; Candrian U; Semini S; Tiberti M; Gobbi C; Zecca C
Mult Scler; 2023 Dec; 29(14):1765-1775. PubMed ID: 37786964
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Rheumatoid Arthritis Information Recorded in UK CPRD Aurum and CPRD GOLD Databases (Companion Paper 3).
Vasilakis-Scaramozza C; Hagberg KW; Persson R; Kafatos G; Maskell J; Neasham D; Jick S
Clin Epidemiol; 2023; 15():1207-1218. PubMed ID: 38126003
[TBL] [Abstract][Full Text] [Related]
6. Association Between Diseases and Symptoms Diagnosed in Primary Care and the Subsequent Specific Risk of Multiple Sclerosis.
Guinebretiere O; Nedelec T; Gantzer L; Lekens B; Durrleman S; Louapre C
Neurology; 2023 Dec; 101(24):e2497-e2508. PubMed ID: 38052493
[TBL] [Abstract][Full Text] [Related]
7. Presence of Breast Cancer Information Recorded in United Kingdom Primary Care Databases: Comparison of CPRD Aurum and CPRD GOLD (Companion Paper 1).
Hagberg KW; Vasilakis-Scaramozza C; Persson R; Neasham D; Kafatos G; Jick S
Clin Epidemiol; 2023; 15():1183-1192. PubMed ID: 38126005
[TBL] [Abstract][Full Text] [Related]
8. Background incidence rates of health outcomes in populations at risk for Lyme disease using US administrative claims data.
Dreyfus J; Munnangi S; Bengtsson C; Correia B; Figueiredo R; Stark JH; Zawora M; Riddle MS; Maguire JD; Jiang Q; Ianos C; Naredo Turrado J; Svanström H; Bailey S; DeKoven M
Vaccine; 2024 Feb; 42(5):1094-1107. PubMed ID: 38262807
[TBL] [Abstract][Full Text] [Related]
9. Phenotypes and rates of cancer-relevant symptoms and tests in the year before cancer diagnosis in UK Biobank and CPRD Gold.
Barclay M; Renzi C; Antoniou A; Denaxas S; Harrison H; Ip S; Pashayan N; Torralbo A; Usher-Smith J; Wood A; Lyratzopoulos G
PLOS Digit Health; 2023 Dec; 2(12):e0000383. PubMed ID: 38100737
[TBL] [Abstract][Full Text] [Related]
10. Outcomes and Health Care Service Use in Adults 50 Years or Older With and Without Multiple Sclerosis: A 6-Year Observational Analysis.
Freeman L; Lucas A; Zhou J; Hayward B; Gough M; Livingston T
Int J MS Care; 2023; 25(2):56-62. PubMed ID: 36923575
[TBL] [Abstract][Full Text] [Related]
11. Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2.
Willis MD; Robertson NP
J Neurol; 2020 May; 267(5):1567-1569. PubMed ID: 32303837
[No Abstract] [Full Text] [Related]
12. An Italian programme for COVID-19 infection in multiple sclerosis.
Sormani MP;
Lancet Neurol; 2020 Jun; 19(6):481-482. PubMed ID: 32359409
[No Abstract] [Full Text] [Related]
13. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
Zheng C; Kar I; Chen CK; Sau C; Woodson S; Serra A; Abboud H
CNS Drugs; 2020 Sep; 34(9):879-896. PubMed ID: 32780300
[TBL] [Abstract][Full Text] [Related]
14. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.
Bar-Or A; Calkwood JC; Chognot C; Evershed J; Fox EJ; Herman A; Manfrini M; McNamara J; Robertson DS; Stokmaier D; Wendt JK; Winthrop KL; Traboulsee A
Neurology; 2020 Oct; 95(14):e1999-e2008. PubMed ID: 32727835
[TBL] [Abstract][Full Text] [Related]
15. Effects of MS disease-modifying therapies on responses to vaccinations: A review.
Ciotti JR; Valtcheva MV; Cross AH
Mult Scler Relat Disord; 2020 Oct; 45():102439. PubMed ID: 32769063
[TBL] [Abstract][Full Text] [Related]
16. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis.
Louapre C; Collongues N; Stankoff B; Giannesini C; Papeix C; Bensa C; Deschamps R; Créange A; Wahab A; Pelletier J; Heinzlef O; Labauge P; Guilloton L; Ahle G; Goudot M; Bigaut K; Laplaud DA; Vukusic S; Lubetzki C; De Sèze J; ; Derouiche F; Tourbah A; Mathey G; Théaudin M; Sellal F; Dugay MH; Zéphir H; Vermersch P; Durand-Dubief F; Françoise R; Androdias-Condemine G; Pique J; Codjia P; Tilikete C; Marcaud V; Lebrun-Frenay C; Cohen M; Ungureanu A; Maillart E; Beigneux Y; Roux T; Corvol JC; Bordet A; Mathieu Y; Le Breton F; Boulos DD; Gout O; Guéguen A; Moulignier A; Boudot M; Chardain A; Coulette S; Manchon E; Ayache SS; Moreau T; Garcia PY; Kumaran D; Castelnovo G; Thouvenot E; Taithe F; Poupart J; Kwiatkowski A; Defer G; Derache N; Branger P; Biotti D; Ciron J; Clerc C; Vaillant M; Magy L; Montcuquet A; Kerschen P; Coustans M; Guennoc AM; Brochet B; Ouallet JC; Ruet A; Dulau C; Wiertlewski S; Berger E; Buch D; Bourre B; Pallix-Guiot M; Maurousset A; Audoin B; Rico A; Maarouf A; Edan G; Papassin J; Videt D
JAMA Neurol; 2020 Sep; 77(9):1079-1088. PubMed ID: 32589189
[TBL] [Abstract][Full Text] [Related]
17. Infections in patients with multiple sclerosis: A national cohort study in Sweden.
Castelo-Branco A; Chiesa F; Conte S; Bengtsson C; Lee S; Minton N; Niemcryk S; Lindholm A; Rosenlund M; Piehl F; Montgomery S
Mult Scler Relat Disord; 2020 Oct; 45():102420. PubMed ID: 32736217
[TBL] [Abstract][Full Text] [Related]
18. Multiple sclerosis and COVID-19: How many are at risk?
Bsteh G; Bitschnau C; Hegen H; Auer M; Di Pauli F; Rommer P; Deisenhammer F; Berger T
Eur J Neurol; 2021 Oct; 28(10):3369-3374. PubMed ID: 32978860
[TBL] [Abstract][Full Text] [Related]
19. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Sormani MP; De Rossi N; Schiavetti I; Carmisciano L; Cordioli C; Moiola L; Radaelli M; Immovilli P; Capobianco M; Trojano M; Zaratin P; Tedeschi G; Comi G; Battaglia MA; Patti F; Salvetti M;
Ann Neurol; 2021 Apr; 89(4):780-789. PubMed ID: 33480077
[TBL] [Abstract][Full Text] [Related]
20. Vaccination in multiple sclerosis - Challenging practices (Review).
Sirbu CA; Florea AA; Ghinescu MC; Docu-Axelerad A; Sirbu AM; Bratu OG; Radu FI
Exp Ther Med; 2020 Dec; 20(6):217. PubMed ID: 33149781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
